Hamlet BioPharma Expands US Clinical Trial for Bladder Cancer

Hamlet BioPharma has expanded its clinical trials in the United States through a collaboration with the University of Iowa. The newly expanded trial will focus on high-risk, resistant non-muscle-invasive bladder cancer (NMIBC), an aggressive form of the disease.

The expansion includes a partnership with the University of Iowa, reinforcing the company's commitment to advancing cancer therapies. Hamlet BioPharma maintains a broad portfolio of projects aimed at treating cancer and infectious diseases.

Earlier in June, the company also prepared for a Phase III trial of its Alpha1H treatment in Prague and reported continued success with its new anti-infective therapies.

Based in Lund, Sweden, Hamlet BioPharma is dedicated to developing novel treatments for cancer and infections.